Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non-Current Liabilities: 2021-2025

Historic Other Non-Current Liabilities for Foghorn Therapeutics (FHTX) over the last 2 years, with Sep 2025 value amounting to $656,000.

  • Foghorn Therapeutics' Other Non-Current Liabilities was N/A to $656,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $656,000, marking a year-over-year change of. This contributed to the annual value of $29,000 for FY2022, which is 79.72% down from last year.
  • Foghorn Therapeutics' Other Non-Current Liabilities amounted to $656,000 in Q3 2025, which was down 13.34% from $757,000 recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Other Non-Current Liabilities high stood at $856,000 for Q1 2025, and its period low was $29,000 during Q4 2022.
  • In the last 1 years, Foghorn Therapeutics' Other Non-Current Liabilities had a median value of $757,000 in 2025 and averaged $756,333.
  • Data for Foghorn Therapeutics' Other Non-Current Liabilities shows a maximum YoY tumbled of 79.72% (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows Foghorn Therapeutics' Other Non-Current Liabilities stood at $143,000 in 2021, then tumbled by 79.72% to $29,000 in 2022, then reached $656,000 in 2025.
  • Its Other Non-Current Liabilities was $656,000 in Q3 2025, compared to $757,000 in Q2 2025 and $856,000 in Q1 2025.